Literature DB >> 16699315

Pathologic findings of lung tumors diagnosed on baseline CT screening.

Douglas B Flieder1, Madeline Vazquez, Darryl Carter, Elizabeth Brambilla, Adi Gazdar, Masayuki Noguchi, William D Travis, Arin Kramer, David F Yankelevitz, Claudia I Henschke.   

Abstract

Sixty-five people had a resection of their baseline screen-diagnosed lung cancers in the Early Lung Cancer Action Program. Forty-nine of the carcinomas were solitary, and 42 of these were adenocarcinomas. More than 1 carcinoma was found in 16 patients after pathologic examination of the lobectomy specimen; 15 of the 16 second carcinomas were adenocarcinomas, mixed subtype. Eighteen cases were submitted by local pathologists as Bronchioloalveolar carcinomas but were found to be invasive adenocarcinomas according to the World Health Organization classification by the Pathology Review Panel. Of the 65 resected cases, 57 were N0, 7 were N1, and 1 was N2. Upon careful review of the lobectomy specimens, 49 cases had solitary malignancies, 30 were Stage IA, 13 Stage IB, 3 Stage IIA, 2 Stage IIB, and 1 Stage IIIA on the basis of the American Joint Committee on Cancer/International Union for Cancer Control criteria. In the 16 cases found to have multiple malignancies, 6 had histologically different carcinomas and the remaining 10 had histologically identical malignancies. Eighty-three percent (76/92) of the carcinomas invaded the stroma with destruction of normal lung, and 21% (19/92) also showed either pleural or angiolymphatic invasion, even though 88% (57/65) of the carcinomas were free of lymph node metastases. This report describes the pathologic findings of the resected cases. Histopathologic distinctions among atypical adenomatous hyperplasia, bronchioloalveolar carcinomas, and invasive adenocarcinoma are described in detail.

Entities:  

Mesh:

Year:  2006        PMID: 16699315     DOI: 10.1097/01.pas.0000202040.51967.d0

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

1.  The evolving role of the pathologist in the management of lung cancer.

Authors:  Adi F Gazdar
Journal:  Lung Cancer Manag       Date:  2012

2.  Multifocal lung cancers--clonality vs field cancerization and does it matter?

Authors:  Adi F Gazdar; John D Minna
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

3.  Pulmonary adenocarcinoma histology.

Authors:  Erik Thunnissen
Journal:  Transl Lung Cancer Res       Date:  2012-12

4.  Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions.

Authors:  Jon O Ebbert; Laveena Chhatwani; Marie Christine Aubry; Jason Wampfler; Shawn Stoddard; Fang Zhang; Guibin Qiao; Mariza de Andrade; Ping Yang
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

5.  Can image analysis on high-resolution computed tomography predict non-invasive growth in adenocarcinoma of the lung?

Authors:  Yukihiro Yoshida; Miki Sakamoto; Eriko Maeda; Hiroshi Ohtsu; Satoshi Ota; Hisao Asamura; Jun Nakajima
Journal:  Ann Thorac Cardiovasc Surg       Date:  2014-04-18       Impact factor: 1.520

6.  Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.

Authors:  Adi Gazdar; Linda Robinson; Dwight Oliver; Chao Xing; William D Travis; Junichi Soh; Shinichi Toyooka; Lori Watumull; Yang Xie; Kemp Kernstine; Joan H Schiller
Journal:  J Thorac Oncol       Date:  2014-04       Impact factor: 15.609

7.  KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.

Authors:  Alyssa M Krasinskas; Simon I Chiosea; Timothy Pal; Sanja Dacic
Journal:  Mod Pathol       Date:  2013-07-26       Impact factor: 7.842

8.  Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications.

Authors:  Madeline Vazquez; Darryl Carter; Elizabeth Brambilla; Adi Gazdar; Masayuki Noguchi; William D Travis; Yao Huang; Lijuan Zhang; Rowena Yip; David F Yankelevitz; Claudia I Henschke
Journal:  Lung Cancer       Date:  2008-10-31       Impact factor: 5.705

Review 9.  The importance of the regimen of screening in maximizing the benefit and minimizing the harms.

Authors:  Claudia I Henschke; Kunwei Li; Rowena Yip; Mary Salvatore; David F Yankelevitz
Journal:  Ann Transl Med       Date:  2016-04

10.  Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening.

Authors:  A W Castleberry; D Smith; C Anderson; A J Rotter; F W Grannis
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.